VAP Prevention Mouthpiece with Novel Essential Oil
Value Proposition
This specialized mouthguard prevents Ventilator-Associated Pneumonia (VAP) in mechanically ventilated patients. It utilizes a novel coating of essential oil with FDA-approved medical-grade polyurethane to maintain an antimicrobial effect. Studies have shown that the lethal pathogens found in the lower respiratory tract of diagnosed VAP patients are also found in the oral cavity, harbored in dental plaque and saliva. The aspiration of bacteria-laden, secretions past the endotracheal tube (ETT) balloon/cuff is proven to be a primary source of VAP.
Competitive Advantage
Prevents the pooling of secretions above the ETT cuff through absorption of saliva
Improves oral cavity microbiome through the complete surface area contact/coverage of all tooth surfaces and the gum line
Unique Features
Continuous, effective protection against VAP at the origin of the problem
Reduces the need for labor-intensive oral care regimens currently handled non-compliantly by ICU nursing staff
Fits seamlessly within current workflows as a small, disposable, easy to use, inventoried product
Essential Oil Unique Properties:
Even in low weight coatings, this product retains swell capacity to absorb oral secretions and maintain antimicrobial effect
Versatile application methods including brush, dip, and spray
Optimized for common VAP pathogens
Licensing Information
Optioned by Prevada in 2022
Principal Investigators
Kevin Ward, MD
Scott VanEpps MD, PhD
Anish Tuteja, PhD
Intellectual Property
Invention Disclosure # 6329, 2018-334
Patents Issued: US8042544, US9457163, US10751494
Solution Sheet
Download Solution Sheet (PDF)
Broadly acknowledged as one of the leading causes of morbidity and mortality in the ICU environment, ventilator-associated pneumonia (VAP) is a type of hospital-acquired infection (HAI) that develops in patients requiring mechanical ventilation. The diagnosis and treatment of VAP costs the US healthcare system approximately $12B each year and costs many lives as well, accounting for 60% of all HAI-related deaths. VAP is directly responsible for increased antibiotic use, extended hospitalizations, and an overall (non-reimbursed) cost to the hospital of $40K+ per incident.
Our cost-effective, easy-to-implement solution provides additional protection against VAP-related pathogens without impeding current workflows or requiring labor intensive and risky reintubation procedures.
Please contact the Licensing Manager, Jeremy Nelson , for more information.
Funding History
Substantial departmental, school and center based support